The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.
 
Jennifer Eads
Employment - Janssen Oncology (I); Merus (I)
Stock and Other Ownership Interests - Janssen Oncology (I); Merus (I)
Consulting or Advisory Role - Daiichi Sankyo; Exelixis; Lantheus Medical Imaging; Merck; Oncolys BioPharma
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Chimeric Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Hutchison MediPharma (Inst); Merck (Inst); Oncolys BioPharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Exelixis; Janssen Oncology (I)
 
Maria Pia Morelli
No Relationships to Disclose
 
Daniel Olson
Consulting or Advisory Role - Alphasights; Expert Consulting Services; Gerson Lehrman Group; Iovance Biotherapeutics; MJH Life Sciences; Novartis; Novartis; Obsidian Therapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Jason Litten
Employment - Chimeric Therapeutics
Leadership - Chimeric Therapeutics
Stock and Other Ownership Interests - Artiva; Chimeric Therapeutics
Consulting or Advisory Role - Notch Therapeutics; Sastra Cell Therapy
 
Stephanie Astrow
Employment - Chimeric Therapeutics; Fate Therapeutics
Stock and Other Ownership Interests - Chimeric Therapeutics
Travel, Accommodations, Expenses - Chimeric Therapeutics
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)